From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director

Bell Direct
July 7, 2025

In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:
·      (0:47): An overview of PIQ and its FY26 goals
·      (1:38): The significance of three world-first blood tests
·      (5:26): The global addressable markets for these conditions
·      (6:25): Clinical trial progress and commercialisation roadmap
·      (8:14): How the diagnostic tests work and deliver value to patients
·      (9:16): Commercialisation strategy across key regions
·      (11:23): Additional assets in the PIQ pipeline
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

Equity Investor 20 March

Julia Lee
March 20, 2018

Market Update

Julia Lee
March 19, 2018

Equity Investor 12 February

Julia Lee
March 14, 2018

Market Update

Julia Lee
March 8, 2018

Equity Investor

Julia Lee
March 6, 2018

Market Update

Julia Lee
March 6, 2018

Market Update

Julia Lee
March 6, 2018

Market Update

Julia Lee
March 2, 2018

Equity Investor

Julia Lee
February 27, 2018

Market Update

Julia Lee
February 21, 2018

Equity Investor 19 February

Julia Lee
February 20, 2018

Market Update

Julia Lee
February 19, 2018